Anti-TLR2 antibody and use thereof
The anti-TLR2 antibody addresses the lack of effective treatments for Multiple System Atrophy by reducing disease markers and inflammatory responses, promoting nerve recovery, providing a promising therapeutic approach for MSA.
Patent Information
- Application Number
- PCT/KR2023/006350
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-09
- Filing Date
- 2023-05-10
- Publication Date
- 2024-11-14
AI Technical Summary
Current treatments for Multiple System Atrophy (MSA) are limited, with no definitive cause known and only symptom management available, leading to a need for effective therapeutic options.
Development of an anti-TLR2 antibody, specifically binding to Toll-Like Receptor 2, which reduces disease markers, inflammatory bodies, and promotes nerve bundle recovery, as demonstrated by its effectiveness in in vitro and in vivo models.
The anti-TLR2 antibody significantly reduces disease markers, inflammatory responses, and improves cellular and nerve bundle health in MSA models, offering a potential treatment and prevention strategy for MSA.
Smart Images

Figure KR2023006350_14112024_PF_FP_ABST
Abstract
Description
Anti-TLR2 antibodies and uses thereof
[0001] The present invention relates to a novel use of an anti-TLR2 antibody, and more particularly, to the use of an anti-TLR2 antibody for preventing or treating multiple system atrophy.
[0002] As human lifespans increase, the incidence of neurodegenerative diseases, including Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's disease, Alzheimer's disease, multiple system atrophy, multi-infarct dementia, and discoid macular degeneration, is also increasing. It is estimated that 24 million people worldwide currently suffer from neurodegenerative diseases. Furthermore, the incidence of other forms of neurodegenerative diseases, such as those caused by stroke or other trauma or injury, is increasing annually.
[0003] According to statistics from the Health Insurance Review & Assessment Service, a total of 1,951 patients received hospital treatment for multiple system atrophy in 2020, more than doubling in just five years from 926 in 2016.
[0004] Multiple System Atrophy (MSA), in particular, is a rare, progressive neurodegenerative disease characterized by a complex array of symptoms. Patients with this disease share Parkinson's-like symptoms, including cerebellar ataxia and autonomic failure, which affects heart rate, blood pressure, sweating, and bowel and bladder control. However, the exact cause of MSA remains unknown. Currently, there are no treatments, and medications aimed at symptom control are sometimes prescribed, such as the levodopa / carbidopa combination known as Sinemet, which is also used to treat Parkinson's disease.
[0005] Accordingly, the inventors of the present invention completed the present invention by confirming the excellent treatment effect of anti-TLR2 antibody for multiple system atrophy symptoms while conducting research to develop a treatment agent for multiple system atrophy.
[0006] Accordingly, the purpose of the present invention is to provide a composition for preventing or treating multiple system atrophy, comprising an antibody or an antigen-binding fragment thereof that specifically binds to TLR2 (Toll-Like Receptor 2).
[0007] Another object of the present invention is to provide a method for treating multiple system atrophy comprising administering to a subject an effective amount of an antibody or an antigen-binding fragment thereof that specifically binds to TLR2.
[0008] In order to achieve the above object, the present invention provides a pharmaceutical composition for preventing or treating multiple system atrophy, comprising an antibody or an antigen-binding fragment thereof that specifically binds to TLR2, comprising a heavy chain variable region comprising a heavy chain CDR1 comprising an amino acid sequence of SEQ ID NO: 1, a heavy chain CDR2 comprising an amino acid sequence of SEQ ID NO: 2, and a heavy chain CDR3 comprising an amino acid sequence of SEQ ID NO: 3; and a light chain variable region comprising a light chain CDR1 comprising an amino acid sequence of SEQ ID NO: 4, a light chain CDR2 comprising an amino acid sequence of SEQ ID NO: 5, and a light chain CDR3 comprising an amino acid sequence of SEQ ID NO: 6.
[0009] In addition, the present invention provides a veterinary composition for preventing or treating multiple system atrophy, comprising an antibody or an antigen-binding fragment thereof that specifically binds to TLR2, comprising a heavy chain variable region comprising a heavy chain CDR1 comprising an amino acid sequence of SEQ ID NO: 1, a heavy chain CDR2 comprising an amino acid sequence of SEQ ID NO: 2, and a heavy chain CDR3 comprising an amino acid sequence of SEQ ID NO: 3; and a light chain variable region comprising a light chain CDR1 comprising an amino acid sequence of SEQ ID NO: 4, a light chain CDR2 comprising an amino acid sequence of SEQ ID NO: 5, and a light chain CDR3 comprising an amino acid sequence of SEQ ID NO: 6.
[0010] The present invention also provides a method for treating multiple system atrophy, comprising administering to a subject an effective amount of an antibody or an antigen-binding fragment thereof that specifically binds to TLR2, wherein the antibody comprises a heavy chain variable region comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 1, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and a light chain variable region comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 5, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 6.
[0011] The anti-TLR2 antibody according to the present invention exhibits a remarkable effect of reducing the expression of disease markers, reducing inflammatory bodies, and restoring nerve bundles at the multiple system atrophy cell and animal level, and thus can be utilized in various fields of prevention, improvement, and treatment of multiple system atrophy.
[0012] Figure 1 is a diagram showing the results of confirming the characteristics of an in vitro multiple system atrophy cell model using human neural stem cells.
[0013] Figure 2 is a diagram showing the results of confirming DNA damage in an in vitro multiple system atrophy cell model using human neural stem cells.
[0014] Figure 3 is a diagram showing the results of confirming the cell aging phenomenon in an in vitro multiple system atrophy cell model using human neural stem cells.
[0015] Figure 4 is a diagram showing the results of confirming the GCI reduction effect according to NM-103 treatment in an in vitro multiple system atrophy cell model using human neural stem cells.
[0016] Figure 5 is a diagram showing the results of evaluating the effect of NM-103 treatment on reducing DNA damage in an in vitro multiple system atrophy cell model using human neural stem cells.
[0017] Figure 6 is a diagram showing the results of confirming the effect of reducing cell aging according to NM-103 treatment in an in vitro multiple system atrophy cell model using human neural stem cells.
[0018] Figure 7 is a diagram showing the results of analyzing the survival rate of individuals according to NM-103 treatment in an in vivo multiple system atrophy model.
[0019] Figure 8 is a diagram showing the results of confirming the effect of NM-103 treatment on improving motor ability in an in vivo multiple system atrophy model.
[0020] Figure 9 is a diagram showing the results of confirming the GCI reduction effect according to NM-103 treatment in an in vivo multiple system atrophy model.
[0021] Figure 10a is a diagram showing the results of confirming the effect of reducing neuroinflammation according to NM-103 treatment in the cerebral cortex of an in vivo multiple system atrophy model.
[0022] Figure 10b is a diagram showing the results of confirming the effect of NM-103 treatment on reducing neuroinflammation in the brain white matter of an in vivo multiple system atrophy model.
[0023] Figure 10c is a diagram showing the results of confirming the effect of reducing neuroinflammation according to NM-103 treatment in the hippocampus of an in vivo multiple system atrophy model.
[0024] Figure 10d is a diagram showing the results of confirming the effect of reducing neuroinflammation according to NM-103 treatment in the striatum of an in vivo multiple system atrophy model.
[0025] Figure 10e is a diagram showing the results of confirming the effect of NM-103 treatment on reducing neuroinflammation in the midbrain substantia nigra of an in vivo multiple system atrophy model.
[0026] Figure 11 is a diagram confirming the effect of NM-103 treatment on reducing inflammatory bodies in an in vivo multiple system atrophy model.
[0027] Figure 12 is a diagram confirming the nerve bundle recovery effect according to NM-103 treatment in an in vivo multiple system atrophy model.
[0028] Hereinafter, the present invention will be described in detail.
[0029] According to an aspect of the present invention, the present invention provides a composition for preventing or treating multiple system atrophy, comprising an antibody or an antigen-binding fragment thereof that specifically binds to TLR2, wherein the antibody comprises a heavy chain variable region comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 1, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and a light chain variable region comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 5, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 6. The composition for preventing or treating multiple system atrophy according to the present invention may be a pharmaceutical composition or a veterinary composition.
[0030] As used herein, the term "antibody" refers to an anti-TLR2 antibody that specifically binds to TLR2. The scope of the present invention includes not only complete antibody forms that specifically bind to TLR2, but also antigen-binding fragments of such antibody molecules.
[0031] A complete antibody is a structure having two full-length light chains and two full-length heavy chains, each light chain linked to a heavy chain by a disulfide bond.
[0032] As used herein, the term "heavy chain" refers to a full-length heavy chain and fragments thereof, which comprises a variable domain VH comprising an amino acid sequence having sufficient variable region sequence to confer specificity to an antigen, and three constant region domains CH1, CH2, and CH3. In addition, the term "light chain" as used herein refers to a full-length light chain and fragments thereof, which comprises a variable domain VL comprising an amino acid sequence having sufficient variable region sequence to confer specificity to an antigen, and a constant region domain CL.
[0033] The above whole antibodies include subtypes of IgA, IgD, IgE, IgM and IgG, and in particular, IgG includes IgG1, IgG2, IgG3 and IgG4. The heavy chain constant region has gamma (γ), mu (μ), alpha (α), delta (δ) and epsilon (ε) types, and has subclasses of gamma1 (γ1), gamma2 (γ2), gamma3 (γ3), gamma4 (γ4), alpha1 (α1) and alpha2 (α2). The light chain constant region has kappa (κ) and lambda (λ) types.
[0034] Antigen-binding fragments of antibodies, or antibody fragments, refer to fragments that possess antigen-binding function, and include Fab, F(ab'), F(ab')2, and Fv. Among antibody fragments, Fab has a structure with variable regions of the light and heavy chains, a constant region of the light chain, and the first constant region (CH1) of the heavy chain, and has one antigen-binding site. Fab' differs from Fab in that it has a hinge region containing one or more cysteine residues at the C-terminus of the heavy chain CH1 domain. F(ab')2 is generated when the cysteine residues in the hinge region of Fab' form a disulfide bond.
[0035] Fv is the smallest antibody fragment that contains only a heavy chain variable region and a light chain variable region. A two-chain Fv has a heavy chain variable region and a light chain variable region non-covalently linked, while a single-chain Fv (single-chain Fv, scFv) has a heavy chain variable region and a light chain variable region covalently linked, usually via a peptide linker, or directly linked at the C-terminus, so that it can form a dimer-like structure like a two-chain Fv. These antibody fragments can be produced using proteolytic enzymes (for example, restriction digestion of a complete antibody with papain yields Fab, and digestion with pepsin yields F(ab')2) or using genetic recombination technology.
[0036] An "Fv" fragment is an antibody fragment containing the complete antibody recognition and binding site. This region is a dimer composed of one heavy chain variable domain and one light chain variable domain.
[0037] The "Fab" fragment comprises the variable and constant domains of the light chain and the variable and first constant domain (CH1) of the heavy chain. An F(ab')2 antibody fragment typically comprises a pair of Fab' fragments covalently linked by cysteines in the hinge region at the C-terminus of the Fab' fragment.
[0038] A "single-chain Fv (scFv)" antibody fragment is a construct consisting of a single polypeptide chain comprising the VH and VL domains of an antibody. The scFv may additionally comprise a polypeptide linker between the VH and VL domains that allows it to form the desired structure for antigen binding.
[0039] In one embodiment, the antibodies of the present invention include, but are not limited to, monoclonal antibodies, multispecific antibodies, human antibodies, humanized antibodies, chimeric antibodies, scFv, Fab fragments, F(ab')2 fragments, disulfide-linked Fvs (sdFv), and anti-idiotypic (anti-Id) antibodies or epitope-binding fragments of the foregoing antibodies.
[0040] The heavy chain constant region can be selected from any one of the gamma (γ), mu (μ), alpha (α), delta (δ), or epsilon (ε) isotypes. For example, the constant region is gamma 1 (IgG1), gamma 2 (IgG2), gamma 3 (IgG3), or gamma 4 (IgG4). The light chain constant region can be kappa or lambda type.
[0041] The term "monoclonal antibody" refers to antibodies obtained from a substantially homogeneous population of antibodies, i.e., antibodies that are identical except for possible naturally occurring mutations that may be present in trace amounts in individual antibodies within the population. Monoclonal antibodies are highly specific, being directed against a single antigenic site. In contrast to conventional (polyclonal) antibodies, which typically contain different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen.
[0042] "Epitope" refers to a protein determinant to which an antibody can specifically bind. Epitopes are typically composed of chemically active surface molecules, such as amino acids or sugar side chains, and typically have specific three-dimensional structural features as well as specific charge characteristics. Conformational and non-conformational epitopes are distinguished by the fact that binding to the former is lost in the presence of denaturing solvents, while binding to the latter is not.
[0043] The above "humanized" forms of non-human (e.g., mouse) antibodies are chimeric antibodies that contain minimal sequence derived from a non-human immunoglobulin. In most cases, humanized antibodies are human immunoglobulins (recipient antibody) in which residues from the hypervariable region of the recipient antibody have been replaced with residues from the hypervariable region of a non-human species (donor antibody) that retains the desired specificity, affinity, and ability, such as mouse, rat, rabbit, or non-human primate.
[0044] The above "human antibody" means a molecule derived from human immunoglobulin, and the entire amino acid sequence constituting the antibody, including the complementarity determining region and structural region, is composed of human immunoglobulin.
[0045] "Chimeric" antibodies (immunoglobulins) in which a portion of the heavy and / or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies that exhibit the desired biological activity.
[0046] The "variable region" of an antibody used in the present invention refers to the light chain and heavy chain portions of an antibody molecule, including the amino acid sequences of the complementarity determining regions (CDRs; i.e., CDR1, CDR2, and CDR3) and the framework regions (FR). VH refers to the variable domain of the heavy chain. VL refers to the variable domain of the light chain.
[0047] "Complementary Determining Region (CDR)" refers to the amino acid residues in an antibody variable domain that are necessary for antigen binding. Each variable domain typically has three CDR regions, identified as CDR1, CDR2, and CDR3.
[0048] "Framework regions (FR)" are variable domain residues other than CDR residues. Each variable domain typically has four FRs: FR1, FR2, FR3, and FR4.
[0049] In a specific embodiment of the present invention, the antibody that specifically binds to TLR2 preferably includes a heavy chain variable region represented by the amino acid sequence of SEQ ID NO: 7.
[0050] In a specific embodiment of the present invention, it is preferable that the antibody specifically binding to TLR2 includes a light chain variable region represented by the amino acid sequence of SEQ ID NO: 8.
[0051] In a specific embodiment of the present invention, it is preferable that the antibody specifically binding to TLR2 comprises a heavy chain represented by the amino acid sequence of SEQ ID NO: 9; and a light chain represented by the amino acid sequence of SEQ ID NO: 10.
[0052] The antibody or antibody fragment of the present invention may include not only the sequence of the anti-TLR2 antibody of the present invention described herein, but also biological equivalents thereof, as long as it can specifically recognize TLR2. For example, additional changes may be made to the amino acid sequence of the antibody to further improve the binding affinity and / or other biological properties of the antibody. Such modifications include, for example, deletions, insertions, and / or substitutions of amino acid sequence residues of the antibody. Such amino acid mutations are made based on the relative similarity of the amino acid side chain substituents, such as hydrophobicity, hydrophilicity, charge, size, etc. Analysis of the size, shape, and type of amino acid side chain substituents reveals that arginine, lysine, and histidine are all positively charged residues; alanine, glycine, and serine have similar sizes; and phenylalanine, tryptophan, and tyrosine have similar shapes. Therefore, based on these considerations, arginine, lysine, and histidine; Alanine, glycine and serine; and phenylalanine, tryptophan and tyrosine are biologically functional equivalents.
[0053] Considering the mutations having the above-described biological equivalent activity, the antibody of the present invention is interpreted to also include a sequence showing substantial identity with the sequence described in the sequence number. The substantial identity means a sequence showing at least 90% homology, most preferably at least 95% homology, 96% or more, 97% or more, 98% or more, or 99% or more homology when the sequence of the present invention and any other sequence are aligned to the greatest extent possible and the aligned sequence is analyzed using an algorithm commonly used in the art. Alignment methods for sequence comparison are known in the art. The NCBI Basic Local Alignment Search Tool (BLAST) is accessible from NBCI, etc., and can be used in conjunction with sequence analysis programs such as blastp, blasm, blastx, tblastn, and tblastx on the Internet. BLAST can be accessed at www.ncbi.nlm.nih.gov / BLAST / . How to compare sequence homology using this program can be found at www.ncbi.nlm.nih.gov / BLAST / blast_ help.html.
[0054] Based on this, the antibody or antigen-binding fragment thereof of the present invention may have 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more homology with the specified sequence or the entire sequence described in the specification. Such homology may be determined by sequence comparison and / or alignment using methods known in the art. For example, the percent sequence homology of the nucleic acid or protein of the present invention may be determined using a sequence comparison algorithm (i.e., BLAST or BLAST 2.0), manual alignment, or visual inspection.
[0055] In the present invention, “prevention” means any act of suppressing clinical symptoms of a disease or delaying progression by administering a composition according to the present invention, and “treatment” means suppressing the development of clinical symptoms of a disease, alleviating or eliminating clinical symptoms of a disease.
[0056] When the composition of the present invention is a pharmaceutical composition, it may further comprise a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier included in the composition of the present invention is one commonly used in formulation, and includes, but is not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, water, syrup, methyl cellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil. In addition to the above components, the composition of the present invention may further comprise a lubricant, a wetting agent, a sweetener, a flavoring agent, an emulsifier, a suspending agent, a preservative, and the like.
[0057] The pharmaceutical composition of the present invention can be administered orally or parenterally, and in the case of parenteral administration, can be administered by intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, intradermal administration, topical administration, intranasal administration, intrapulmonary administration, and rectal administration.
[0058] Since proteins or peptides are digested when administered orally, oral compositions must be formulated to coat the active agent or protect it from degradation in the stomach. Furthermore, the pharmaceutical composition can be administered using any device capable of transporting the active agent to the target cells.
[0059] The appropriate dosage of the composition according to the present invention varies depending on factors such as the formulation method, administration method, patient's age, weight, sex, pathological condition, food, administration time, administration route, excretion rate, and response sensitivity. A skilled physician can easily determine and prescribe a dosage effective for the desired treatment or prevention. For example, the daily dosage of the pharmaceutical composition of the present invention is 0.0001-100 mg / kg. The term "pharmaceutically effective amount" as used herein means an amount sufficient to prevent or treat cancer or an infectious disease.
[0060] The pharmaceutical composition of the present invention can be manufactured in a unit dose form or can be manufactured by inserting it into a multi-dose container by formulating it using a pharmaceutically acceptable carrier and / or excipient according to a method that can be easily performed by a person having ordinary skill in the art to which the present invention pertains. In this case, the formulation may be in the form of a solution, suspension or emulsion in an oil or aqueous medium, or in the form of an extract, powder, suppository, powder, granule, tablet or capsule, and may additionally include a dispersing agent or stabilizer.
[0061] When the composition of the present invention is a veterinary composition, the composition of the present invention may additionally contain appropriate excipients and diluents commonly used in the manufacture of veterinary compositions.
[0062] Excipients and diluents that may be included in the veterinary composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, cetanol, stearyl alcohol, liquid paraffin, sorbitan monostearate, polysorbate 60, methylparaben, propylparaben, and mineral oil.
[0063] The veterinary composition of the present invention may further comprise fillers, anticoagulants, lubricants, wetting agents, flavoring agents, emulsifiers, preservatives, etc. The veterinary composition of the present invention may be formulated using methods well known in the art so as to provide rapid, sustained, or delayed release of the active ingredient after administration to an animal. The formulation may be in the form of powders, granules, tablets, capsules, suspensions, emulsions, solutions, syrups, aerosols, soft or hard gelatin capsules, suppositories, sterile injectable solutions, sterile topical preparations, etc. The veterinary composition of the present invention thus formulated may be administered via various routes including orally, transdermally, subcutaneously, intravenously, epidurally, or intramuscularly.
[0064] The veterinary composition of the present invention may vary depending on the age, sex, and weight of the animal, but may be administered once or several times daily in an amount of 0.1 to 100 mg / kg. Furthermore, the dosage of β-NGF may be increased or decreased depending on the route of administration, severity of the disease, sex, body weight, age, etc. The above dosage does not limit the scope of the present invention in any way.
[0065]
[0066] According to another aspect of the present invention, the present invention provides a method for treating multiple system atrophy, comprising administering to a subject an effective amount of an antibody or an antigen-binding fragment thereof that specifically binds to TLR2, the antibody comprising a heavy chain variable region comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 1, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and a light chain variable region comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 5, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 6.
[0067] In a specific example of the present invention, the subject may be, but is not limited to, a subject expected to develop multiple system atrophy; a subject that has developed the disease; or a subject that has been judged to be cured.
[0068]
[0069] Duplicate contents are omitted in consideration of the complexity of this specification, and terms not otherwise defined in this specification have meanings commonly used in the technical field to which the present invention belongs.
[0070] Hereinafter, the present invention will be described in more detail through examples. These examples are intended solely to illustrate the present invention, and it will be apparent to those skilled in the art that the scope of the present invention is not limited by these examples.
[0071]
[0072] [Experimental Example]
[0073] Experimental Example 1. Method for Differentiating Human Neural Stem Cells (hNSCs) into Oligodendrocytes
[0074] To form oligospheres, hNSCs were cultured in Oligodendrocyte Progenitor Cells (OPCs) medium for 7 days. These were dissociated into single OPCs and cultured in OPCs medium for 5 days. After culture, the medium was replaced with oligodendrocyte differentiation medium and cultured for an additional 14 days to obtain mature oligodendrocytes.
[0075]
[0076] Experimental Example 2. Treatment of differentiating oligodendrocytes with extracellular a-Synuclein
[0077] a-Syn conditioned medium (SCM) was treated at a concentration of 1000 ng / mL for 72 hours, and LacZ CM (LZCM), used as a control, was treated at the same volume as aSCM. The experiment was conducted at day 11 of oligodendrocyte differentiation, matching the point at which oligodendrocyte differentiation ended and the end of 72 hours of CM treatment.
[0078]
[0079] Experimental Example 3. NM-103 treatment of differentiating oligodendrocytes.
[0080] NM-103 was used at 10 μg / mL and 50 μg / mL and pretreated 30 minutes before CM treatment.
[0081]
[0082] Experimental Example 4. Immunofluorescence staining
[0083] Cells were fixed with 4% PFA (in PBS) on coverslips. The fixed cells were treated with 0.1% Triton X-100 and then washed with PBS. The washed cells were treated with blocking solution (5% bovine serum albumin and 3% goat serum in PBS) and then washed. The cells were treated with primary antibodies diluted in blocking solution for 16 hours. The cells treated with the primary antibodies were washed. The cells treated with the primary antibodies were washed, and the washed cells were treated with secondary antibodies conjugated with the fluorescent dyes Alexa488, Cy2, Rhodamine red-X, or Alexa647 for 2 hours. The cells treated with the secondary antibodies were washed with PBS. Nuclei were additionally stained with Hoechst 33342. The coverslips were used to prepare slides using mounting solution. The slides were then observed and analyzed using a Zeiss LSM 900 with Airyscan 2 (Zeiss, Oberkochen, Germany).
[0084]
[0085] Experimental Example 5. Tg Mouse Animal Experiment
[0086] aSyn A53T Tg mice (line G2-3), which express the human aSyn A53T gene under the PrP promoter, were used as a model of MSA disease. NM-103 was administered to diseased mice at 6 months of age to conduct an in vivo efficacy evaluation.
[0087]
[0088] Experimental Example 6. Immunofluorescence staining using brain tissue sections
[0089] Sections were obtained from mouse brain tissue fixed with 4% PFA using a cryotome device. The sections were permeabilized with a solution of 0.2% Triton X-100 and 0.5% NGS (Normal Goat Serum). The sections were then washed with phosphate-buffered saline (PBS) and treated with primary antibodies for 16 hours. The sections treated with primary antibodies were washed with PBS and then treated with secondary antibodies for 2 hours under light-shielding conditions for immunofluorescence staining. The stained brain tissues were mounted using coverslips and slides and observed using a Zeiss LSM 900 with Airyscan 2 (Zeiss, Oberkochen, Germany).
[0090]
[0091] Experimental Example 7. Analysis of Nerve Myelin Using TEM
[0092] Brain tissue was fixed with 4% formalin and 1% glutaraldehyde and stirred at 4°C for 16 h. After stirring, it was postfixed with 1% osmium tetroxide for 30 min. The brain tissue samples were treated with epoxy resin and dehydrated with ethanol solutions (70%, 80%, 85%, 90%, 95%, and 100%). Brain tissue sections were obtained using an ultramicotome, and then sample slices were obtained on copper grids and stained with uranyl acetate and lead citrate. The prepared tissues were imaged with a cryo-TEM to observe the neural sheath.
[0093]
[0094] [Example]
[0095] Example 1. Establishment of an in vitro MSA disease cell model using human neural stem cells.
[0096] Human neural stem cells (hNSCs) were differentiated to obtain oligodendrocytes (OLs). The differentiated OLs were treated with aSyn Conditioned Media (aSCM) containing high amounts of the disease-associated toxic protein alpha-synuclein (aSyn) for 72 hours to establish an in vitro multiple system atrophy (MSA) cell model. The results of confirming the constructed in vitro MSA cell model are shown in Figure 1.
[0097] As shown in Fig. 1, when OLs differentiated from hNSCs were treated with aSCM, TPPP / p25a and ubiquitin were detected colocalized with aSyn. The TPPP / p25a ubiquitin is a characteristic of glial cytoplasmic inclusions (GCIs) found in MSA patients.
[0098]
[0099] Example 2. Confirmation of DNA damage and cellular senescence in an in vitro MSA disease cell model.
[0100] Through immunohistochemical staining, DNA damage and cell senescence phenomena in the in vitro MSA disease cell model constructed in Example 1 were confirmed. The results of confirming DNA damage in the in vitro MSA disease cell model are shown in Fig. 2, and the results of confirming cell senescence phenomena are shown in Fig. 3.
[0101] As shown in Fig. 2, DNA damage associated with degenerative brain diseases was confirmed in an in vitro MSA cell model induced by aSCM treatment.
[0102] As shown in Fig. 3, the cellular aging phenomenon associated with degenerative brain diseases was confirmed in an in vitro MSA cell model induced by aSCM treatment.
[0103]
[0104] Example 3. Establishment of an in vitro MSA disease cell model treated with NM-103.
[0105] The in vitro MSA disease cell model constructed in Example 1 was treated with 50 μg / mL of NM-103 30 minutes prior to 72-hour aSCM treatment. NM-103 is an anti-TLR2 (toll-like receptor 2) antibody, also known as Tomaralimab. The specific sequence is shown in Table 1.
[0106] Name Sequence Number Sequence NM-103Heavy Chain CDR11TTYGINCDR22GWIYPRDGSTNFNENFKDCDR33LTGGTFLDYLight Chain CDR14RASESVEYYGTSLMQCDR25GASNVESCDR36QQSRKLPWTHeavy Chain Variable Region7QVQLVQSGSELKKPGASVKLSCKASGFTFTTYGINWVRQAPGQGLEWIGWIYPRDGSTNFNENFKDRATITVDTSASTAYMELSSLRSEDTAVYFCARLTGGTFLDYWGQGTTVTVSSLight Chain Variable Region8DIVLTQSPATLSLSPGERATLSCRASESVEYYGTSLMQWYQQKPGQPPKLLIFGASNVESGVPDRFSGSGSGTDFTLKISRVEAEDVGMYFCQQSRKLPWTFGGGTKVEIKHeavy Chain Full sequence 9QVQLVQSGSELKKPGASVKLSCKASGFTFTTYGINWVRQAPGQGLEWIGWIYPRDGSTNFNENFKDRATITVDTSASTAYMELSSLRSEDTAVYFCARLTGGTFLDYW GQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYG PPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTI SKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGKLight ChainFull sequence 10DIVLTQSPATLSLSPGERATLSCRASESVEYYGTSLMQWYQQKPGQPPKLLIFGASNVESGVPDRFSGSGSGTDFTLKISRVEAEDVGMYFCQQSRKLPWTFGGGT KVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
[0107]
[0108] Example 4. Evaluation of the efficacy of NM-103 in an in vitro MSA disease cell model.
[0109] 4-4. GCI reduction, a phenomenon of MSA disease caused by NM-103
[0110] The GCI-reducing efficacy of NM-103 was evaluated in an in vitro MSA disease cell model, and the results are shown in Fig. 4.
[0111] As shown in Fig. 4, when the anti-TLR2 antibody NM-103 was treated in an in vitro MSA disease cell model, it was confirmed that the serine 129-phosphorylated form of alpha-synuclein (pS129-aSyn), a GCI disease marker, was reduced.
[0112]
[0113] 4-2. Reduction of DNA damage, a phenomenon of MSA disease, by NM-103
[0114] The DNA damage-reducing effect of NM-103 was evaluated in an in vitro MSA disease cell model, and the results are shown in Fig. 5.
[0115] As shown in Figure 5, when the anti-TLR2 antibody NM-103 was treated in an in vitro MSA disease cell model, it was confirmed that the DNA damage marker 53BP1 (p53-binding protein 1) was reduced.
[0116]
[0117] 4-3. Reduction of cellular aging symptoms, a phenomenon of MSA disease, by NM-103
[0118] The effect of NM-103 on reducing cell senescence was evaluated in an in vitro MSA disease cell model, and the results are shown in Fig. 6.
[0119] As shown in Fig. 6, when the in vitro MSA disease cell model was treated with the anti-TLR2 antibody NM-103, it was confirmed that the cellular senescence marker H3K9m3 was reduced.
[0120]
[0121] Example 5. Experimental study on the therapeutic efficacy of NM-103 in an MSA in vivo model using alpha-synuclein disease mutant overexpressing mice.
[0122] 5-1. Survival rate according to NM-103 treatment
[0123] The survival rate of individuals treated with NM-103 in an in vivo MSA model was analyzed. NM-103 was injected intravenously (IV) into the tail vein. The results of the survival rate analysis are shown in Figure 7.
[0124] As shown in Figure 7, the MSA in vivo model (TG mouse) showed a gradual increase in deaths over time, with a survival rate of 50%. In contrast, the NM-103 administration group (TG mouse + NM-103 3 mg / kg, TG mouse + NM-103 10 mg / kg) showed a 100% survival rate.
[0125]
[0126] 5-2. Improvement of motor ability following NM-103 treatment
[0127] Through GST and Pole Test behavioral experiments, we confirmed the improved motor ability following NM-103 treatment in an in vivo MSA model. The results confirming the improved motor ability are shown in Figure 8.
[0128] As shown in Figure 8, the NM-103 administration group (TG mouse+NM-103 3 mg / kg, TG mouse+NM-103 10 mg / kg) showed improved motor ability.
[0129]
[0130] 5-3. Reduction of MSA pathological marker GCI by NM-103
[0131] Fluorescence staining analysis was used to confirm the expression of the MSA marker GCI in response to NM-103 treatment in an in vivo MSA model. The results confirming GCI expression are shown in Figure 9.
[0132] As shown in Figure 9, the NM-103 administration group (TG mouse+NM-103 3 mpk, TG mouse+NM-103 10 mpk) confirmed that GCI, a MSA disease-specific marker, was reduced in Oligodendrocytes.
[0133]
[0134] 5-4. Reduction of neuroinflammation in an MSA mouse model by NM-103
[0135] Fluorescent staining analysis confirmed the neuroinflammation-reducing effect of NM-103 treatment in an in vivo MSA model. The results confirming the neuroinflammation-reducing effect of NM-103 in the cerebral cortex, white matter, hippocampus, striatum, and substantia nigra are shown in Figures 10a to e, respectively.
[0136] As shown in Figures 10a to e, the NM-103 administration group (TG mouse+NM-103 3 mpk, TG mouse+NM-103 10 mpk) showed a reduction in brain neuroinflammation (GFAP, Iba-I) markers induced by glial cell activity in various brain regions (cerebral cortex, cerebral white matter, cerebral hippocampus, striatum, and midbrain substantia nigra).
[0137]
[0138] 5-6. Reduction of inflammatory bodies in an MSA mouse model by NM-103
[0139] The FLICA assay confirmed the inflammatory reduction effect of NM-103 treatment in an MSA in vivo model. The results confirming the inflammatory reduction effect are shown in Figure 11.
[0140] As shown in Figure 11, the MSA model (TG) showed an increase in inflammatory bodies in oligodendrocytes. In contrast, the NM-103 administration group (TG mouse+NM-103 3 mpk, TG mouse+NM-103 10 mpk) showed a decrease in inflammatory bodies.
[0141]
[0142] 5-7. Recovery of nerve bundles in an MSA mouse model by NM-103
[0143] The neuronal recovery effect of NM-103 treatment was confirmed in an MSA in vivo model. The results confirming the neuronal recovery effect are shown in Figure 12.
[0144] As shown in Figure 12, the MSA model (TG) showed increased myelin damage and demyelination. In contrast, the NM-103-administered group (TG mouse+NM-103 3 mpk, TG mouse+NM-103 10 mpk) showed protection of myelin and suppression of demyelination (i.e., nerve bundle recovery).
[0145]
[0146] While specific aspects of the present invention have been described in detail, it will be apparent to those skilled in the art that these specific descriptions merely represent preferred embodiments and are not intended to limit the scope of the present invention. Therefore, the substantial scope of the present invention is defined by the appended claims and their equivalents.
Claims
1. Heavy chain CDR1 comprising the amino acid sequence of sequence number 1, A heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2 and A heavy chain variable region comprising a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and A light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4, A light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 5 and A pharmaceutical composition for preventing or treating multiple system atrophy, comprising an antibody or an antigen-binding fragment thereof that specifically binds to TLR2 (toll-like receptor 2) comprising a light chain variable region comprising a light chain CDR3 comprising the amino acid sequence of sequence number 6.
2. In paragraph 1, A composition comprising an antibody that specifically binds to the above TLR2 and a heavy chain variable region represented by the amino acid sequence of SEQ ID NO:
7.
3. In paragraph 1, A composition comprising an antibody that specifically binds to the above TLR2 and a light chain variable region represented by the amino acid sequence of SEQ ID NO:
8.
4. In paragraph 1, Antibodies that specifically bind to the above TLR2 A heavy chain represented by the amino acid sequence of sequence number 9; and A composition comprising a light chain represented by the amino acid sequence of SEQ ID NO:
10.
5. Heavy chain CDR1 comprising the amino acid sequence of sequence number 1, A heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2 and A heavy chain variable region comprising a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and A light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4, A light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 5 and A veterinary composition for preventing or treating multiple system atrophy, comprising an antibody or an antigen-binding fragment thereof that specifically binds to TLR2 (toll-like receptor 2) comprising a light chain variable region comprising a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:
6.
6. Heavy chain CDR1 comprising the amino acid sequence of sequence number 1, A heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2 and A heavy chain variable region comprising a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and A light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4, A light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 5 and A method for treating multiple system atrophy, comprising administering to a subject an effective amount of an antibody or an antigen-binding fragment thereof that specifically binds to TLR2 (Toll-Like Receptor 2), comprising a light chain variable region comprising a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 6.
Citation Information
Patent Citations
Humanised antibodies to toll-like receptor 2 and uses thereof
KR101572171B1
Toll-like receptor 2 genes and their polypeptides forrepressing neuropathic pain and Methods of ScreeningAnti-pain Agent by using them
KR1020070042297A
Novel bispecific antibody binding to human TLR2 and human TLR4
US20160355602A1
